What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion at a target dose of 1 × 10\^6 CAR-positive T cells/kg (maximum dose 100 × 10\^6 CAR-positive T cells).”In the company’s words, NCT07729826 on ClinicalTrials.gov
- Tested for
- Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases, Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), MS and 10 more
- Main trialPhase 2
- “This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory lupus nephritis who are not responding to standard therapy. Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of C-CAR168. Participants will be followed for 104 weeks (approximately 2 years) to evaluate renal response, safety, CAR T-cell persistence,…”In the company’s words, NCT07729826 on ClinicalTrials.gov
Other drugs for Lupus Nephritis (LN)
- AnifrolumabAstraZeneca · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- IanalumabNovartis · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
Coming up3
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- Feb 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 31 Dec 2028 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy | |
| Phase 1/2Not yet recruiting | Feb 2030 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy | |
| Phase 1Not yet recruiting | Dec 2028 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy | |
| Phase 1/2Withdrawn | May 2029 | C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026